AstraZeneca's Strong First Quarter Includes Significant Emerging Markets Growth
This article was originally published in The Pink Sheet Daily
Executive Summary
In China alone, the Big Pharma notes net sales were up 36 percent year over year.
You may also be interested in...
AstraZeneca Outlines Branded Generics Strategy at Emerging Markets Event
AZ's emerging markets strategy includes selective entry into branded generics
AZ Taps India's Torrent to Add Branded Generics in Emerging Markets
Innovation-only AstraZeneca gets the branded generics religion, at least in emerging markets.
AZ Continues To Buy Pipeline With $100M Rigel Deal
Facing a raft of patent expiries, AstraZeneca pays richly for Rigel's Phase II oral RA candidate.